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Beta-2 microglobulin (β2m) is an essential component of the major histocompatibility
complex (MHC) class I proteins and in the nervous system β2m is predominantly
expressed in motor neurons. As β2m can promote nerve regeneration, we investigated
its potential role in amyotrophic lateral sclerosis (ALS) by investigating its expression
level as well as the effect of genetically removing β2m on the disease process in
mutant superoxide dismutase 1 (SOD1G93A) mice, a model of ALS. We observed a strong
upregulation of β2m in motor neurons during the disease process and ubiquitous removal
of β2m dramatically shortens the disease duration indicating that β2m plays an essential
and positive role during the disease process. We hypothesize that β2m contributes to
plasticity that is essential for muscle reinnervation. Absence of this plasticity will lead to
faster muscle denervation and counteracting this process could be a relevant therapeutic
target.
Keywords: beta-2 microglobulin, amyotrophic lateral sclerosis, motor neuron, neurodegeneration, motor neuron
disease
INTRODUCTION
Major histocompatibility complex (MHC) class I proteins were
originally discovered based on their critical role in the immune
system, however immune-independent functions in the nervous
system have recently been identified (Huh et al., 2000; Elmer
and Mcallister, 2012). Beta-2 microglobulin (β2m) is an essen-
tial component of MHC class I molecules, being required for
expression of all MHC class I on the cell surface. Within the
central nervous system β2m has a predominantly motor neuronal
expression pattern (Linda et al., 1998, 1999; Thams et al., 2009).
This protein is therefore a candidate to contribute to the selective
vulnerability of such motor neurons during amyotrophic lateral
sclerosis (ALS).
ALS is a progressive neurodegenerative disease, characterized
by the selective loss ofmotor neurons and the denervation ofmus-
cle fibers, resulting in muscle weakness and paralysis. In Europe,
the disease has an annual incidence of 2.7 cases per 100,000 people
(Logroscino et al., 2010) and the disease duration post-diagnosis
is 3–5 years. In 10% of patients, ALS is a familial disease and
20% of these familial ALS patients contain mutations in the gene
encoding superoxide dismutase 1 (SOD1). Based on these muta-
tions, ALS rodent models have been generated that predictably
mimic the patient disease process (Julien and Kriz, 2006). As
the disease progression is indistinguishable between familial and
sporadic ALS, common disease mechanisms are predicted. One
of these mechanisms is decreased (peripheral) neuronal plasticity
that can influence the ability of neuronal networks to compensate
for a loss of (motor) neurons in the network. β2m is expressed
in motor neurons in the lumbar spinal cord (Linda et al., 1999)
as well as in motor axons (Thams et al., 2009). Additionally,
β2m promotes recovery after axotomy (Linda et al., 1998; Oliveira
et al., 2004) and sciatic nerve crush (Oliveira et al., 2004), which
implies that it may be of importance in ALS too.
In this study, we investigated the role of β2m in ALS mice. To
this end, we assessed the gene expression of β2m and interbred
mice genetically lacking β2m with SOD1G93A mice and assessed
survival and disease pathology.
MATERIALS AND METHODS
ANIMAL EXPERIMENTS
Mice overexpressing human wild-type SOD1 (SOD1WT) or
human SOD1G93A and β2m knockout mice were purchased from
The Jackson Laboratories (Bar Harbor, USA) and maintained on
a C57BL/6 background. The SOD1G93A and β2m knockout were
interbred allowing for approx. 50% of the mice to be littermate
controlled in this study. Chow and water were provided ad libitum
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and mice were housed in the specific pathogen free animal facility
of the KU Leuven under standard conditions according to the
guidelines of the KU Leuven. End stage was defined as the age at
which mice could no longer right themselves within 30 s when
placed on their back. End stage is used as a measurement of
survival and is the condition at which mice are euthanized to
prevent further suffering. Disease onset was defined as the age
at which mouse weight dropped below 90% of the average day
90–105 weight. The animal caretakers and scientists were blinded
to the genotypes of themice when assessing “end stage”. All animal
experiments were performed with the approval of the Animal
Ethical Committee of KU Leuven (020/2010).
LASER DISSECTION MICROSCOPY
Murine spinal cords were snap-frozen in Tissue-Tec (Sakura
Finetek Europe, Alphen aan de Rijn, The Netherlands) to make
cryostat sections of 20-µm thickness. Then, cresyl violet–stained
motor neurons, located in the ventral horn of the lumbar spinal
cord, were collected on membrane slides 1.0 PEN (Carl Zeiss
AG, Oberkochen, Germany), using dissection by a laser-dissection
microscope (Carl Zeiss AG) and capturing in Adhesive Cap 500
opaque (Carl Zeiss AG). Onlymotor neurons in which the nucleus
was visible and with soma area > 250µm2, were collected. At least
1,500 motor neurons were dissected for each animal.
QUANTITATIVE PCR
Isolation of mRNA was performed using the TriPure (Roche,
Basel, Switzerland) method and the RNeasy kit (Qiagen,
Venlo, The Netherlands). Reverse transcriptase polymerase chain
reaction (PCR) used random hexamers (Life Technologies,
Carlsbad, USA) and Moloney Murine Leukemia Virus Reverse
Transcriptase (MMLV RT; Invitrogen, Carlsbad, USA). Quanti-
tative PCR (qPCR) was performed with the StepOnePlus (Life
Technologies) and TaqMan Universal PCRMaster Mix (Life Tech-
nologies). Gene expression assays were purchased from Life Tech-
nologies and IDT DNA (Coralville, USA): gapdh (Mm.PT.39a.1),
β2m (Mm00437762_m1) and cd8b1 (Mm.PT49a.10182911). For
this analysis, presymptomatic tissue was collected at 90 days
of age and symptomatic at 120 days of age. The scientist
performing the qPCR was blinded to the genotypes of the
samples.
NISSL STAINING
To visualize neurons, Nissl staining was performed on 4%
formaldehyde fixed spinal cords sections. Sections were briefly
immersed in a cresyl violet solution and subsequently in a
70% ethanol with 10% acetic acid. Slides were dehydrated by
an increased ethanol concentration series and mounted with
PerTex (Histolab AB, Goteborg, Sweden). Images were collected
by Zeiss Axio Imager M1 microscope (Carl Zeiss AG) with Axio-
Cam Mrc5 camera (Carl Zeiss AG). The number of (motor)
neurons was quantified by measurement of the soma area as
visualized by cresyl violet staining in ImageJ (National Institute
of Health) on multiple 40 µm thick sections in the ventral horn
of the lumbar spinal cord. Characterisation of motor neurons
occurred as previously (Fischer et al., 2004) of at least 5–10 ventral
horns of the lumbar spinal cord of 2–4 mice per group. The
scientist performing the Nissl staining and neuron quantification
was blinded to the genotypes of the samples.
IMMUNOHISTOCHEMISTRY
Mice were transcardially perfused with phosphate buffered saline
(PBS) and subsequently with 4% formaldehyde. Spinal cords
were post-fixed with 4% formaldehyde overnight at 4◦C and
transferred to 30% sucrose for an additional night. After snap
freezing, tissue was sectioned by cryostat at 40 µm thickness
and stained with a polyclonal antibody directed against ubiquitin
(Dako, Glostrup, Denmark). Images were collected by Zeiss Axio
Imager M1 microscope (Carl Zeiss AG) with AxioCam Mrc5
camera (Carl Zeiss AG). Ubiquitin immunopositive aggregates
were counted per ventral horn using ImageJ of 2–6 ventral
horns of the lumbar spinal cord of 2–4 mice per group and
presented as the average of the number of aggregates per ventral
horn. The scientist performing the immunohistochemistry and
aggregate quantification was blinded to the genotypes of the
samples.
STATISTICAL ANALYSIS
Analysis was performed with the statistical software package
Prism Origin (GraphPad Software, La Jolla, USA). Survival was
analyzed by Log-Rank testing. Differences between two groups
were analyzed using a Student’s t-test. Differences between more
than two groups were analyzed by ANOVA with Bonferroni cor-
rection for multiple testing. Significance was assumed at p < 0.05.
Error bars represent the standard deviation.
RESULTS
To assess the potential for β2m to have a functional role in ALS
pathogenesis, we assessed gene expression in the spinal cords
of non-transgenic, SOD1WT and SOD1G93A mice. We observed
a strong increase in β2m gene expression during disease pro-
gression in SOD1G93A mice (Figure 1A). This increase is at least
partly due to the increased neuron-specific gene expression of
β2m, as a greater level of upregulation (10-fold) was identified
by qPCR on neurons from SOD1G93A mice compared to neurons
from SOD1WT mice isolated by laser dissection microscopy
(Figure 1B). As we do not observe an increase of CD8+ T cells
in the spinal cord of end stage SOD1G93A mice, as assessed by the
gene expression analysis ofCD8b1 (Figure 1C), these data indicate
potential for a neuronal role for β2m in ALS.
To determine whether β2m has an effect in ALS, we interbred
β2m−/− mice with SOD1G93A mice and assessed disease pro-
gression in β2m−/− SOD1G93A, β2m+/− SOD1G93A and β2m+/+
SOD1G93A mice. The survival of β2m+/− SOD1G93A mice did not
differ from β2m+/+ SOD1G93A littermates (data not shown). The
complete genetic ablation of β2m did not affect onset of disease
(data not shown), but significantly decreased average survival
of SOD1G93A mice by 8.9 days (Figure 2A) and reduced disease
duration by approximately 50% (Figure 2B). The decrease of
survival in β2m−/− SOD1G93A mice demonstrated a protective
role for β2m in ALS mice.
To assess whether genetic ablation of β2m alters pathology
of SOD1G93A mice, we analyzed pathology in the spinal cords
of end stage mice. Decreased numbers of motor neurons were
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FIGURE 1 | Increased β2m gene expression in ALS mice. (A) Relative
β2m gene expression in spinal cord of non-transgenic (ntg, n = 6) and
SOD1WT controls (n = 6) compared to presymtomatic (presympt, n =
6), symptomatic (sympt, n = 6) and end stage (n = 6) SOD1G93A
mice (ANOVA, Bonferroni post hoc). (B) Relative β2m gene expression
in neurons isolated by laser dissection microscopy from the spinal cord
of SOD1WT controls at 60 days (n = 2) and 130 days of age (n = 3)
compared to neurons from SOD1G93A mice at 60 days (n = 3) and
130 days of age (n = 3; Student’s t-test). (C) Relative CD8b1 gene
expression in the spinal cord of 150 day old non-transgenic mice (ntg,
n = 5) and end stage (n = 5) SOD1G93A mice. *p < 0.05, **p <
0.01, ****p < 0.0001.
FIGURE 2 | Decreased survival in β2m knockout ALS mice. (A) Survival analysis of β2m+/− SOD1G93A (n = 13, 154.9 ± 7.7 days) and β2m−/− SOD1G93A
mice (n = 11, 146.0 ± 8.8 days; Log-Rank p = 0.009). (B) Disease duration of β2m+/− SOD1G93A (n = 9) and β2m−/− SOD1G93A mice (n = 8). *p < 0.05.
observed in the end stage spinal cord of SOD1G93A and β2m−/−
SOD1G93A mice (Figures 3A–C, quantified in Figure 3D), as were
increased ubiquitin-positive aggregates (Figures 3E–G, quantified
in Figure 3H). No differences were observed between the end
stage pathology of SOD1G93A and β2m−/− SOD1G93A mice for
motor neurons (Figures 3B, C) or ubiquitin immunoreactivity
(Figures 3F, G). This shows that end stage β2m−/− SOD1G93A
mice show the same extent of motor neuron loss and aggregate
formation as end stage SOD1G93A mice, although disease progres-
sion is faster.
DISCUSSION
Here we show that β2m is important in ALS mouse survival and
that it is upregulated during disease in the spinal cord and by
motor neurons. Upregulation of β2m in neuronal tissues has been
reported previously when comparing spinal cord (Edstrom et al.,
2004) and brain (VanGuilder Starkey et al., 2012) expression of
aged rats to adult controls and in the spinal cord of axotomised
rats (Maehlen et al., 1988; Olsson et al., 1989; Linda et al.,
1998), whichmay suggest that stressed neurons increase β2m gene
expression to increase plasticity. This concept fits well with reports
of the role of β2m in neurons during development and plasticity
(Huh et al., 2000; Bilousova et al., 2012), of the hippocampus
and visual system (Huh et al., 2000) but not of the cerebellum
(Letellier et al., 2008), and the delayed or impaired recovery of
β2m knockout mice post axotomy (Linda et al., 1998; Oliveira
et al., 2004) and sciatic nerve crush (Oliveira et al., 2004).
Impaired (peripheral) plasticity by β2m knockoutmay explain
the decrease in survival detected in ALS mice in this study, as
increased plasticity is protective in ALSmice and rats (VanHoecke
et al., 2012). A number of plasticity-promoting genetic or phar-
macological strategies have proven successful in the past in ALS
models, such as EphA4 knockdown and inhibition (Van Hoecke
et al., 2012), and vascular endothelial growth factor (VEGF)
administration in ALS rodents (Storkebaum et al., 2005).
With the use of a ubiquitous β2m knockout mouse we cannot
exclude that the decrease of survival of ALSmice lacking β2mmay
be due to the effect of removing β2m in the immune system. β2m
is necessary for the differentiation of CD8+ T cells and natural
killer T (NKT) cells (Koller et al., 1990). The role of these cell types
is not yet fully understood in ALS, as varying results are obtained
for ALSmouse survival when mature lymphocytes are not present
(Beers et al., 2008; Tada et al., 2011). Additionally, NKT cells may
be associated to ALS disease pathology as impairments in NKT
cells are reported in ALSmice (Finkelstein et al., 2011). That being
said, qPCR analysis of CD8+ T cells does not suggest a role for
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FIGURE 3 | Unaltered end stage pathology in β2m-deficient
SOD1G93A mice. Ventral horns of spinal cord sections of
non-transgenic (ntg, n = 4; A and E) and SOD1G93A (n = 4; B and F)
and β2m−/− SOD1G93A (n = 2; C and G) SOD1G93A mice. Nissl
staining was used to visualize the (motor) neurons (A–C). The number
of > 250 µm2 neurons and > 400 µm2 motor neurons per ventral
horn are quantified in (D) Ubiquitin immunoreactivity in spinal cord
sections of non-transgenic, SOD1G93A and β2m−/− SOD1G93A mice are
quantified in (H) Dashed lines delineate the ventral horn. Scale bar =
100 µm. *p < 0.05, **p < 0.01, ***p < 0.001.
these cells asCD8b1 gene expression is not increased in ALS spinal
cords. Additionally, a role for CD8+ T cells may be predicted to be
detrimental in contrast to our data demonstrating a detrimental
role for β2m upon removal in ALS mice. Interestingly, β2m has
been assessed previously as a biomarker in cerebrospinal fluid or
venous blood samples fromALS patients, but with variable results
(Brettschneider et al., 2008; Mitchell et al., 2009; Baciu et al.,
2012).
The mechanism to which β2m contributes to neuronal plas-
ticity is not fully understood, though it is proposed that it
may be through paired-immunoglobulin like receptor-B (PirB)
(VanGuilder Starkey et al., 2012). This receptor is located on
axons, dendrites and neuronal somata (VanGuilder Starkey et al.,
2012) and could thus easily facilitate plasticity. Additionally,
β2m is localized at synapses and in synaptosomes (Shatz, 2009).
Alternatively, β2m and PirB are associated with decreased plas-
ticity and recovery in other neurodegenerative conditions such
as stroke (Adelson et al., 2012), experimental autoimmune
encephalomyelitis (EAE; Denic et al., 2012) and ischemia (Wang
et al., 2012). These paradigms are largely affected by the immune
system and the beneficial effect of β2m or PirB in these models
may be due to the role of the immune system. This notion is
supported by work by Linker et al. that show that reconstitution
of CD8+ cells in β2m knockout mice delays the effect of EAE
compared to β2m knockout littermates (Linker et al., 2005).
In conclusion, this work shows the detrimental effect of β2m
knockout in ALS and identifies β2m signaling as a potential new
direction for the development of therapeutic strategies counter-
acting ALS.
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